Press releases
Access archived Guidant press releases
Access archived BTG press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
May 3, 2021
Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences. On May 11, 2021, Dan Brennan, executive vice president and chief financial officer, and Susie Lisa,...
-
Apr 28, 2021
Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.752 billion during the first quarter of 2021. This represents growth of 8.2 percent on a reported basis, 5.6 percent on an...
-
Mar 26, 2021
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ending March 31, 2021 on Wednesday, April 28,...
-
Mar 25, 2021Data presented at SIR 2021 confirm safety and dose-efficacy relationship
Boston Scientific Corporation (NYSE: BSX) announced positive data from the TARGET study of the TheraSphere™ Y-90 Glass Microspheres (TheraSphere) – a type of radioembolization comprised of...
-
Mar 18, 2021Treatment is the only radioembolization treatment approved for U.S. patients with hepatocellular carcinoma
Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval of the TheraSphere™ Y-90 Glass Microspheres, developed for the treatment of...
-
Mar 3, 2021Acquisition of a leading laser technology to expand global kidney stone management portfolio
Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement with an affiliate of Baring Private Equity Asia (BPEA) to acquire the global surgical business of...
-
Feb 12, 2021
Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences. On February 25, 2021, Dan Brennan, executive vice president and chief financial officer, and Susie...
-
Feb 3, 2021
Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.708 billion during the fourth quarter of 2020. This represents a decline of (6.8) percent on a reported basis, (8.3) percent on...
-
Jan 22, 2021Fourth-generation DBS portfolio features full-body MR conditional devices
Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval of its fourth-generation Vercise Genus™ Deep Brain Stimulation (DBS) System. The...
-
Jan 21, 2021Acquisition of external cardiac monitoring technologies and services provider to expand rhythm management diagnostics portfolio and capabilities
Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Preventice Solutions, Inc., a privately-held company which offers a full portfolio of...